BC
Therapeutic Areas
Addex Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dipraglurant (ADX48621) | Parkinson's disease levodopa-induced dyskinesia (PD-LID) | Phase 2/3 |
| ADX71149 | Epilepsy | Phase 2 |
| GABAB PAM Program | Chronic Cough, Pain, Anxiety, Addiction | Discovery/Preclinical |
| mGlu7 NAM Program | Stress-related disorders, Anxiety, Depression | Discovery/Preclinical |
Leadership Team at Addex Therapeutics
TD
Tim Dyer
Chief Executive Officer
RL
Robert Lütjens
Head of Discovery
RM
Roger Mills
Chief Medical Officer
SK
Stephan Krämer
Chief Financial Officer
JR
Jean-Philippe Rocher
Board Member
MA
Michael Altorfer
Board Member
DH
David Hallett
Board Member
AP
Antoine Papiernik
Board Member
ND
Nicolas Dunant
Board Member